When a man builds an app that gives people with ALS their voice back, the headline writes itself. What gets left out is what the usual experts are not saying: how late most patients hear about voice banking, how little routine care integrates it, and how far behind the mainstream narrative the institutions still are.
The human-interest story hides the expert gap in ALS care
KSL.com reported in March 2026 on a Pittsburgh-area man who developed an app that gives people with ALS their voice back. David Betts, a consultant with no coding background, built “Talk to Me, Goose!” in 80 days after his wife was diagnosed with ALS at 57. The app uses voice cloning from as little as 45 seconds of audio and an AI assistant, Merlin, to expand short phrases into full sentences. It is free for ALS patients in the U.S. and Canada through Live Like Lou and won the 2026 Zero Project Award. KSL.com and CBS Pittsburgh have rightly told the story of ingenuity and love. What rarely gets the same spotlight is the gap between that kind of innovation and what established medical and advocacy narratives emphasise: drug trials, clinic visits, and standard AAC referrals—often without the urgency or clarity that would get patients to bank their voice before it is too late.
Guidelines do mention communication support, but the emphasis in mainstream discourse is uneven. The European Academy of Neurology’s 2024 ALS management guideline, produced with the European Reference Network for Neuromuscular Diseases, recommends multidisciplinary teams that include speech-language pathologists and access to AAC devices, plus assessment and monitoring of communication needs. Riluzole and, for eligible patients, tofersen are highlighted as disease-modifying options; communication support is listed alongside but rarely gets the same urgency in public messaging. But a scoping review on speech treatment for dysarthria in ALS, cited in MDPI Healthcare in 2025, notes that evidence for when and how to intervene is still evolving. In practice, many patients and families first hear about voice cloning or low-cost apps from media stories like the one on KSL.com, not from a systematic part of the care pathway. The expert gap is not that experts disagree with innovation; it is that the narrative around “what to do” still centres on drugs and devices that take years to reach guidelines, while apps and voice banking are treated as optional or secondary until a headline forces them into view.
Medical innovation in ALS has historically been dominated by drug development and formal assistive-technology trials. The American Journal of Physical Medicine and Rehabilitation and related literature report that assistive technology is central to ALS care because disease-modifying drugs have only modest effects on survival, yet most studies of devices are small pilots. The ALS Association funds assistive technology grants and lists assistive technology as a priority in its progress reports, but the public story of ALS care is still largely one of waiting for the next drug approval. Patient-driven tools like Talk to Me, Goose! and initiatives from ElevenLabs and Apple Personal Voice show what is possible when someone outside the usual pipeline builds for the person in front of them. The gap is that the mainstream narrative does not yet treat that kind of innovation as a first-line message: bank your voice early, ask about apps, demand integration into your care plan.
What experts say and what they leave unsaid
Clinical guidelines increasingly mention AAC and speech-language support. The EAN guideline recommends that teams include speech-language pathologists and that both low- and high-technology AAC be provided based on need, with training for patients and caregivers. ASHA’s evidence maps summarise these recommendations. What the guidelines do not always make explicit is the urgency of voice banking: that once speech is significantly impaired, capturing a usable voice sample becomes impossible. Advocates like Project Revoice and the teams behind apps like Talk to Me, Goose! stress “do not wait”; that message is still not a standard, emphasised part of the first post-diagnosis conversation in many clinics. So the expert gap is not that experts oppose innovation; it is that the systems they work in—reimbursement, referral pathways, and patient education—often lag behind what technology can already do. When a husband builds an app in 80 days and gives it away for free, the contrast with the slow rollout of institutional support is stark. Research on assistive technology in ALS, including scoping reviews in journals such as the American Journal of Physical Medicine and Rehabilitation, notes that most device studies are small and that evidence across disease stages remains limited. That leaves room for patient- and family-driven tools to fill the gap before formal guidelines catch up. KSL.com and CBS Pittsburgh put that story in the spotlight; the next step is for expert bodies and care pathways to make voice banking and app-based options a visible, default part of the narrative from day one.
What This Actually Means
The expert gap is not a conspiracy; it is a lag. Guidelines and institutions are slowly catching up to what patients and families discover in headlines and on app stores. Drug approvals and formal device trials dominate the news cycle; the day-to-day tools that let someone speak in their own voice often depend on a family member or a small team building outside the usual channels. Recognising that gap is the first step toward closing it. The Betts story is a reminder that the best innovations sometimes come from the people closest to the problem. Until “voice banking and accessible apps” are as standard in the first conversation after an ALS diagnosis as riluzole and a multidisciplinary team, the narrative will keep underplaying the very innovations that could help the most people right now. The expert gap is not malice; it is inertia. Closing it means making patient-driven innovation part of the official story, not just the human-interest sidebar. Then the next David Betts will be the rule, not the exception.
Who is David Betts and why did he build Talk to Me, Goose!?
David Betts is a Pittsburgh-area consultant with no prior coding experience. After his wife was diagnosed with ALS at age 57, he was frustrated that existing text-to-speech tools sounded too robotic and did not preserve her voice. He built “Talk to Me, Goose!” in 80 days, launching it in March 2025. The app uses voice cloning from a short audio sample and an AI assistant to turn brief inputs into full sentences, reducing the awkward pauses common with traditional AAC. Betts partnered with the nonprofit Live Like Lou to offer the app free to ALS patients in the U.S. and Canada. In 2026 the app won the Zero Project Award for reducing barriers for people with disabilities. His story illustrates how patient and family need can drive innovation faster than institutional pipelines. The expert gap appears when the mainstream narrative still treats such innovation as a feel-good sidebar instead of a core part of what every person with ALS should hear about at diagnosis.
Sources
KSL.com, CBS Pittsburgh, European Academy of Neurology / Wiley, MDPI Healthcare, ALS Association, American Journal of Physical Medicine and Rehabilitation